ALPRE.PA stock leads intraday movers after a +18.21% jump to €3.70 on EURONEXT on 03 Mar 2026, driven by a 5.05x volume surge versus the 50-day average. This volume spike lifted the high to €3.89 and follows a recent pattern of tight ranges around the 50-day average €3.22. Traders should note the company trades on Europe’s EURONEXT in euros and shows thin free float after a market cap of €12,456,706.00, so price moves can be amplified by modest order flow.

Intraday price action and volume overview for ALPRE.PA stock

ALPRE.PA stock is trading €3.70 intraday on EURONEXT after opening at €3.68 and a prior close of €3.13, with a day low of €3.44 and day high €3.89. Volume today is 8,854.00 versus an average daily volume of 1,753.00, a clear high-volume move that supports the 18.21% rise.

Fundamentals snapshot: valuation and profitability for ALPRE.PA stock

Predilife S.A. (ALPRE.PA) shows an EPS of -1.06 and a trailing PE of -3.00, reflecting negative earnings. Price-to-sales is 17.11 and price-to-book is -2.76, indicating premium pricing relative to current revenue and a negative book value per share -1.15. These metrics signal valuation risk despite the market rally.

Technical setup and momentum indicators for ALPRE.PA stock

Technicals show mixed momentum: RSI 51.32, ADX 35.94 (strong trend) and CCI 108.85 (short-term overbought). The 50-day average is €3.22 and 200-day average €3.32, both below the current price, supporting short-term strength while MACD histogram sits slightly positive at 0.01.

Market context and sector comparison for ALPRE.PA stock

Predilife sits in Healthcare, Medical – Diagnostics & Research, a sector where peers trade higher average PE multiples. The small market cap €12.46m and 190 full-time employees mean company-specific news and licensing progress can move the stock more than broad sector trends.

Meyka AI rates ALPRE.PA with a score out of 100

Meyka AI rates ALPRE.PA with a score out of 100: 65.30 (B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs for information only and are not guaranteed; we are not financial advisors.

News, catalysts and short-term risks for ALPRE.PA stock

Key catalysts include clinical updates or regulatory progress for MammoRisk and DenSeeMammo; the next formal earnings announcement is listed as 2025-10-09. Short-term risks include ongoing losses, long days-sales-outstanding 221.82 and tight liquidity that can magnify moves on low order flow.

Final Thoughts

Key takeaways on ALPRE.PA stock: today’s €3.70 price reflects an intraday liquidity-driven rally with volume 8,854.00 beating the average 1,753.00 by about 5.05x, validating the high-volume mover tag. Fundamentals remain challenged — EPS -1.06 and negative book value — which increases downside risk if clinical or commercial updates fail to arrive. Meyka AI’s forecast model projects a quarterly target of €4.55, implying +23.00% versus the current €3.70, while monthly and yearly model points are €2.76 and €1.65, implying downside in shorter and longer horizons respectively. Forecasts are model-based projections and not guarantees. Traders focused on ALPRE.PA stock should weigh rapid intraday liquidity against weak cash flows and valuation metrics, and consider position size limits given the small market cap and thin shares outstanding 3,917,203.00. For company details see Predilife’s site source and for data reference see the company image and financials source. Meyka AI provides this as an AI-powered market analysis platform signal, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.